

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A06/2018

DESPATCHED ON 11TH SEPTEMBER 2018

HLA PHENOTYPE OF BLOOD DONOR: HLA-A1, A2; B7, B60; Cw7, Cw10; DR4, DR15; DQ6, DQ8

				Summary of Results												
				PBL				T-Cells				B-Cells				
Total tested	10	10	10	10	24	24	24	24	17	17	17	17				
Positive	0	0	0	0	0	1	4	0	0	4	8	6				
Negative	10	10	10	10	24	23	20	24	17	13	9	11				
NT	2	2	2	2	1	1	1	1	8	8	8	8				
% Positive	0.0%	0.0%	0.0%	0.0%	0.0%	4.2%	16.7%	0.0%	0.0%	23.5%	47.1%	35.3%				
% Negative	100.0%	100.0%	100.0%	100.0%	100.0%	95.8%	83.3%	100.0%	100.0%	76.5%	52.9%	64.7%				
Consensus	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Not Assessed	Not Assessed				
HLA Antibody Specificity (Defined By CDC)	DR52	B7 B27 Multi	A10	B7	DR52	B7 B27 Multi	A10	B7	DR52	B7 B27 Multi	A10	B7				
Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment	Without DTT				Without DTT				Without DTT				Comments
				Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
112	YES			NT	NT	NT	NT									Low B-cell viability
119	YES			Negative	Negative	Negative	Negative									
120		YES	YES					Negative	Positive	Positive	Negative	Negative	Positive	Positive	Negative	
133		YES	YES					Negative	Negative	Negative	Negative	NT	NT	NT	NT	Low B-cell viability
139	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Positive	
143		YES						Negative	Negative	Negative	Negative					
147	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	
154		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
157	YES			Negative	Negative	Negative	Negative									
159		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
163		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
169		YES	YES					Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
189	YES			Negative	Negative	Negative	Negative									
190		YES	YES					Negative	Negative	Positive	Negative	NT	NT	NT	NT	Low B-cell viability
193		YES	YES					Negative	Negative	Negative	Negative	NT	NT	NT	NT	Low B-cell viability
194		YES	YES					Negative	Negative	Negative	Negative	NT	NT	NT	NT	Low B-cell viability
195		YES	YES					Negative	Negative	Negative	Negative	NT	NT	NT	NT	Low B-cell viability
197		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Positive	
209		YES	YES					Negative	Negative	Negative	Negative	NT	NT	NT	NT	Low B-cell viability
216		YES	YES					Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
229	YES			Negative	Negative	Negative	Negative									
232		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
235	YES			Negative	Negative	Negative	Negative									
238	YES	YES	YES	NT	NT	NT	NT	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Low cell count
239	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Positive	
245	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	NT	NT	NT	NT	Low B-cell viability
252	YES		YES	Negative	Negative	Negative	Negative					Negative	Negative	Negative	Negative	
260		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
292		YES	YES					NT	NT	NT	NT	NT	NT	NT	NT	Late delivery. Low cell viability
293		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
294		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
297		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A06/2018

DESPATCHED ON 11TH SEPTEMBER 2018

Lab No.	PBL without DTT				T-cell without DTT				B-cell without DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
112	NT	NT	NT	NT									50		
119	1	1	1	1									90		
120					1	2	2	1	1	2	2	1		100	100
133					2	2	2	2	NT	NT	NT	NT	95	95	80
139	1	1	1	1	1	1	1	1	1	6	6	8	99	99	90
143					1	1	1	1						90	
147	1	1	1	1	1	1	1	1	1	1	1	6	100	100	100
154					1	1	1	1	1	1	2	1	75	75	75
157	1	1	1	1									100		
159					1	1	1	1	1	1	8	8		90	70
163					1	1	1	1	1	1	1	1		90	90
169					1	1	4	1	1	1	4	1		97	98
189	1	1	1	1									95		
190					5%	10%	25%	15%	NT	NT	NT	NT		95	
193					-	-	-	-	NT	NT	NT	NT		90	
194					1	1	1	1	NT	NT	NT	NT		98	
195					2	2	2	2	NT	NT	NT	NT		80	
197					-	-	-	-	-	Weak	-	Strong		80	80
209					-	-	-	-	NT	NT	NT	NT		90	
216					1	1	4	1	1	1	4	1		95	95
229	-	-	-	-									90		
232					0%	0%	0%	0%	0%	0%	0%	0%		80	60
235	1	1	2	1									85		
238	NT	NT	NT	NT	1	1	2	1	1	1	1	1		95	90
239	-	-	-	-	-	-	-	-	-	8	8	8	96	96	96
245	1	1	1	1	1	1	1	1	NT	NT	NT	NT	100	100	
252	1	1	1	1					1	1	1	1	65		70
260					-	-	-	-	-	-	-	-		90	70
292					NT	NT	NT	NT	NT	NT	NT	NT		20	15
293					0	0	0	0	0	0	0	0		80	80
294					0	0	0	0	0	2	4	4		100	70
297					1	1	1	1	1	1	1	1		90	90

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A06/2018

DESPATCHED ON 11TH SEPTEMBER 2018

HLA PHENOTYPE OF BLOOD DONOR: HLA-A1, A2; B7, B60; Cw7, Cw10; DR4, DR15; DQ6, DQ8

				Summary of Results												
				PBL				T-Cells				B-Cells				
Total tested	10	10	10	10	22	22	22	22	15	14	13	13				
Positive	0	0	0	0	0	0	1	0	0	0	1	2				
Negative	10	10	10	10	22	22	21	22	15	14	12	11				
NT	2	2	2	2	1	1	1	1	9	10	11	11				
% Positive	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	4.5%	0.0%	0.0%	0.0%	7.7%	15.4%				
% Negative	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	95.5%	100.0%	100.0%	100.0%	92.3%	84.6%				
Consensus	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative				
HLA Antibody Specificity (Defined By CDC)	DR52	B7 B27 Multi	A10	B7	DR52	B7 B27 Multi	A10	B7	DR52	B7 B27 Multi	A10	B7				
Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment	With DTT				With DTT				With DTT				Comments
				Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
112	YES			NT	NT	NT	NT									Low viability
119	YES			Negative	Negative	Negative	Negative									
120		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
133		YES	YES					Negative	Negative	Negative	Negative	NT	NT	NT	NT	Low B-cell viability
139	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	
143		YES						Negative	Negative	Negative	Negative	NT	NT	NT	NT	
147	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
157	YES			Negative	Negative	Negative	Negative									
159		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
163		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
169		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
189	YES			Negative	Negative	Negative	Negative									
190		YES	YES					Negative	Negative	Negative	Negative	NT	NT	NT	NT	Low B-cell viability
193		YES	YES					Negative	Negative	Negative	Negative	NT	NT	NT	NT	Low B-cell viability
194		YES	YES					Negative	Negative	Negative	Negative	NT	NT	NT	NT	Low B-cell viability
195		YES	YES					Negative	Negative	Negative	Negative	NT	NT	NT	NT	Low B-cell viability
197		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	
209		YES	YES					Negative	Negative	Negative	Negative	NT	NT	NT	NT	Low B-cell viability
216		YES	YES					Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
229	YES			Negative	Negative	Negative	Negative									
235	YES			Negative	Negative	Negative	Negative									
238	YES	YES	YES	NT	NT	NT	NT	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Low cell count
245	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	NT	NT	NT	NT	Low B-cell viability
252	YES			Negative	Negative	Negative	Negative					Negative	Negative	Negative	Negative	
260		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
262	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	NT	NT	NT	Low B-cell viability and agglutination
292		YES	YES					NT	NT	NT	NT	NT	NT	NT	NT	Late delivery. Low cell viability
293		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
294		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	NT	NT	Uninterpretable
297		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A06/2018

DESPATCHED ON 11TH SEPTEMBER 2018

Lab No.	PBL with DTT				T-cell with DTT				B-cell with DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
112	NT	NT	NT	NT									50		
119	-	-	-	-									90		
120					1	1	1	1	1	1	1	1		100	100
133					2	2	2	2	NT	NT	NT	NT	95	95	80
139	1	1	1	1	1	1	1	1	1	2	1	8	99	99	90
143					-	-	-	-	NT	NT	NT	NT		90	
147	1	1	1	1	1	1	1	1	1	1	1	1	100	100	100
157	1	1	1	1									100		
159					1	1	1	1	1	1	1	1		90	70
163					1	1	1	1	1	1	1	1		90	90
169					1	1	1	1	1	1	1	1		97	98
189	1	1	1	1									95		
190					5%	10%	10%	5%	NT	NT	NT	NT		95	
193					-	-	-	-	NT	NT	NT	NT		90	
194					1	1	1	1	NT	NT	NT	NT		98	
195					2	2	2	2	NT	NT	NT	NT		80	
197					-	-	-	-	-	-	-	Weak		80	80
209					-	-	-	-	NT	NT	NT	NT		90	
216					1	1	4	1	1	1	4	1		95	95
229	-	-	-	-									90		
235	1	1	2	1									85		
238	NT	NT	NT	NT	1	1	1	1	1	1	1	1		95	90
245	1	1	1	1	1	1	1	1	NT	NT	NT	NT	100	100	
252	1	1	1	1					1	1	1	1	65		70
260					-	-	-	-	-	-	-	-		90	70
262	1	1	1	1	1	1	1	1	1	NT	NT	NT	95	95	60
292					NT	NT	NT	NT	NT	NT	NT	NT		20	15
293					0	0	0	0	0	0	0	0		80	80
294					0	0	0	0	2	2/4	NT	NT		100	70
297					1	1	1	1	1	1	1	1		90	90